Review of vedolizumab for the treatment of ulcerative colitis

doi:10.4292/wjgpt.v7.i1.107

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8602)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

760

WORD

325

HTML

3163

Tables (1-2)

123

Sum=4371

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

463

Download

1265

Sum=1728

Publishing Process of This Article

Item

Count

Browse

1039

Download

1464

Sum=2503

Feb 6, 2016 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastrointest Pharmacol Ther. Feb 6, 2016; 7(1): 107-111
Published online Feb 6, 2016. doi: 10.4292/wjgpt.v7.i1.107

Review of vedolizumab for the treatment of ulcerative colitis

Michelle SY Lau, Her Hsin Tsai

Michelle SY Lau, Her Hsin Tsai, IBD Unit, Gastroenterology Department, Castle Hill Hospital, HEY NHS Trust, Cottingham HU16 5JQ, United Kingdom

Author contributions: Lau MSY carried out all the literature searches and prepared the manuscript; Tsai HH made several revisions and prepared the manuscript for publication.

Conflict-of-interest statement: The authors declare no conflicts of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Her Hsin Tsai, MD, FRCP, IBD Unit, Gastroenterology Department, Castle Hill Hospital, HEY NHS Trust, Castle Road, Cottingham HU16 5JQ, United Kingdom. hhtsai@doctors.org.uk

Telephone: +44-1482-875875 Fax: +44-1482-622049

Received: June 10, 2015
Peer-review started: June 11, 2015
First decision: August 25, 2015
Revised: December 12, 2015
Accepted: December 29, 2015
Article in press: January 4, 2016
Published online: February 6, 2016

Abstract

The review summarises the key data on the efficacy and the safety of vedolizumab in the management of ulcerative colitis.

Keywords: Ulcerative colitis, Vedolizumab, Biological therapy, Pharmacology, Safety and efficacy

Core tip: Vedolizumab appears to be effective in the management of moderate to severe ulcerative colitis with a good safety profile.